Building on previous reports demonstrating the antitumor efficacy of FR054—a competitive inhibitor of PGM3—in breast cancer, pancreatic cancer, and pancreatic ductal adenocarcinoma—we extended these findings to GBM [11, 12, 13]. Here, PGM3 is linked to breast carcinoma.